According to the latest study into the effectiveness of the Pfizer-BioNTech vaccine, roughly one in seven people in the UK have developed antibodies to COVID-19.
The study involved 154-thousand subjects, including more than 17-thousand who had received at least one dose.
Further research also shows that 91-percent of people who received two doses of Pfizer's vaccine had developed antibodies, which rises to 95.5 percent in people under the age of 60.
It added that those aged 80 and older had an 88-percent chance of forming antibodies.
The youngest group, those 30 and under, had a very strong level of antibodies, at 94.7 percent, just three weeks after their first dose.
Over in Italy, the country's virus czar has praised the country's vaccination program. noting that inoculations showed " a comforting increase" this week, averaging around 100-thousand a day nationally.
This comes as Italy's northern Lombardy region asked the national government Thursday for more vaccines to help stem a resurgence.
Italy on Thursday added nearly 20-thousand cases, the highest daily number since early January.
Israel, which has been by far the most aggressive country when it comes to vaccinating its people, has announced its plans to reopen its economy in the near future.
"The fourth stage on the end of March, our intention to finish vaccinating the adult population over the age 16. On April, our intention to reach a full opening. For sure this depends on the level of illness but if we all do what we should do we can pass through this."
Last Sunday, Israel reopened many of its businesses, including leisure facilities, but only to those who had been immunized or for those who have recovered from COVID-19.
The country has administered at least one dose of Pfizer's vaccine to nearly half of its 9 million population so far.
Lee Seung-jae, Arirang News.